Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...

After hours: 7:54:36 p.m. EST ...

A number of agents have antitumor activity in metastatic renal cancer. Most of the new agents are approved based on a comparison with either interleukin 2 or interferon α. But on what basis does ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

And for its part, GSK won't concede that Sirtris' small molecules don't bind the targets. In an e-mailed statement, Ad Rawcliffe, head of GSK's WorldWide Business Development group, says ...

Founded in the heart of the British countryside, the Cotswolds, an area that's famous for its chocolate-box villages and charming country pubs, is the British lifestyle brand Bamford. Sitting ...

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...